Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03260023 |
|
Recruitment Status :
Recruiting
First Posted : August 24, 2017
Last Update Posted : February 15, 2022
|
Sponsor:
Transgene
Collaborators:
Merck KGaA, Darmstadt, Germany
EMD Serono Research & Development Institute, Inc.
Pfizer
Information provided by (Responsible Party):
Transgene
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | December 2023 |
| Estimated Study Completion Date : | December 2024 |